French drugmaker Sanofi announced on Thursday that it has received approval from India’s Central Drugs Standard Control Organization (CDSCO) to market its novel therapy, Beyfortus, in India. The therapy is aimed at protecting newborns and infants from respiratory syncytial virus (RSV).

Sanofi gets drug regulator nod to market RSV therapy in India

Sanofi’s Beyfortus, approved in India, is a monoclonal antibody injection to prevent RSV in infants globally.

Sanofi gets regulatory nod for RSV product in India

The fall in the share price came after the pharmaceutical company reported a weak set of June quarter of financial year 2025 (Q1FY25) results.

Sanofi India stock falls 2% on weak June quarter results; profit falls 16%

Sanofi India standalone net profit declines 15.87% in the June 2024 quarter

Sanofi India Ltd is quoting at Rs 6682, up 1.9% on the day as on 12:44 IST on the NSE. The stock is down 3.35% in last one year as compared to a 23.16% jump in NIFTY and a 44.66% jump in the Nifty Pharma.

Sanofi India Ltd spurts 1.9%, rises for fifth straight session

‘Microbial contamination under investigation’: Sanofi has asked the distributors, hospitals and retailers to halt sales of these products manufactured at the same site. The letter clarifies that this recall is applicable and restricted only to the batch numbers mentioned

Sanofi Initiates Voluntary Recall Of Allegra, Combiflam Suspensions In India Over Contamination Concerns - News18

Sanofi, a leading pharmaceutical company, has announced a collaboration with Hyderabad GCC (Government of Telangana's Genome Valley Biotech Limited) in India. This partnership aims to strengthen Sanofi's presence in the country and expand its operations. The company's expansion plan in India includes investing in research and development, manufacturing facilities, and creating job opportunities. Watch Madeleine Roach, Executive Vice President, Business Operations, Sanofi, on ETNow.

#etnow #businessnews #sharemarket #englishnews #unionbudget2024 #budget2024 #sanofi #sanofistocks #hyderabadgcc #expansionplans #india
Subscribe To ET Now For Latest Updates On Stocks, Business, Trading | ► https://goo.gl/SEjvK3

Subscribe Now To Our Network Channels :-
Times Now  : http://goo.gl/U9ibPb
The NewsHour Debate : http://goo.gl/LfNgFF

To Stay Updated Download the Times Now App :-
Android Google Play :  https://goo.gl/zJhWjC
Apple App Store :  https://goo.gl/d7QBQZ

Social Media Links :-
Twitter - http://goo.gl/hA0vDt
Facebook - http://goo.gl/5Lr4mC
G+ - http://goo.gl/hYxrmj
Website - www.etnownews.com

Sanofi Stocks: Company To Collaborate With Hyderabad GCC, What’s The Expansion plan In India?

The Commission signed deals with COVID vaccine supplies AstraZeneca, Sanofi, GSK, Johnson & Johnson, BioNTech, Pfizer, Moderna and others at the height of the pandemic

EU court criticises Commission over handling of Covid vaccine contracts

The Hyderabad facility is expected to do a significant amount of documentation work related to drug clinical trials, Roach added

Sanofi to invest $437 million in India global centre, double its workforce

Sanofi Healthcare India invests €400 million in Hyderabad Global Development Centre expansion, aiming for excellence and innovation.

Sanofi Healthcare India to invest €400 million in expanding Hyderabad’s GCC

Over next two years, the Hyderabad GCC will become largest of Sanofi’s four global hubs and host about 2,600 employees.

Sanofi To Pump In Nearly Rs 3,600 Crore Into Its Hyderabad Capacity Centre By 2030

Hasn't fared well - amongst the low performers

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is overpriced but is not in the overbought zone

Current price is more than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Sanofi India Limited is engaged in the manufacture and sale of pharmaceutical products.

Sanofi India Ltd